Glaxo Is on Hook for $89.7 Million to Vectura Over Inhalers (2)

GlaxoSmithKline Plc was ordered by a jury to pay Vectura Group Plc $89.7 million in royalties for infringing a patent on inhalers used to treat chronic lung disease.

Breo, Anoro and Incruse, which Glaxo began selling in 2013 as part of its Ellipta suite of treatments, have technology owned by Vectura that helps disperse the medicine deep inside the lungs, according to the jury in Wilmington, Delaware.

Jurors, who deliberated on May 3 for less than two hours, also found the infringement intentional, meaning the judge can increase the award. They rejected Glaxo’s claim that the patent is invalid.

Courtney ...